ID   EPMA_SALTY              Reviewed;         325 AA.
AC   Q9ZJ12;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2002, sequence version 2.
DT   07-APR-2021, entry version 123.
DE   RecName: Full=Elongation factor P--(R)-beta-lysine ligase {ECO:0000255|HAMAP-Rule:MF_00174};
DE            Short=EF-P--(R)-beta-lysine ligase {ECO:0000255|HAMAP-Rule:MF_00174};
DE            EC=6.3.1.- {ECO:0000255|HAMAP-Rule:MF_00174};
DE   AltName: Full=EF-P post-translational modification enzyme A {ECO:0000255|HAMAP-Rule:MF_00174};
DE   AltName: Full=EF-P-lysine lysyltransferase {ECO:0000255|HAMAP-Rule:MF_00174};
GN   Name=epmA {ECO:0000255|HAMAP-Rule:MF_00174}; Synonyms=genX, yjeA;
GN   OrderedLocusNames=STM4344;
OS   Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=99287;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND DISRUPTION PHENOTYPE.
RC   STRAIN=UK-1;
RX   PubMed=9826331; DOI=10.1128/iai.66.12.5599-5606.1998;
RA   Kaniga K., Compton M.S., Curtiss R. III, Sundaram P.;
RT   "Molecular and functional characterization of Salmonella enterica serovar
RT   typhimurium poxA gene: effect on attenuation of virulence and protection.";
RL   Infect. Immun. 66:5599-5606(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=LT2 / SGSC1412 / ATCC 700720;
RX   PubMed=11677609; DOI=10.1038/35101614;
RA   McClelland M., Sanderson K.E., Spieth J., Clifton S.W., Latreille P.,
RA   Courtney L., Porwollik S., Ali J., Dante M., Du F., Hou S., Layman D.,
RA   Leonard S., Nguyen C., Scott K., Holmes A., Grewal N., Mulvaney E.,
RA   Ryan E., Sun H., Florea L., Miller W., Stoneking T., Nhan M., Waterston R.,
RA   Wilson R.K.;
RT   "Complete genome sequence of Salmonella enterica serovar Typhimurium LT2.";
RL   Nature 413:852-856(2001).
RN   [3]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH AMP AND PHOSPHATE,
RP   FUNCTION IN EF-P MODIFICATION, LYSYLATION ACTIVITY, SUBUNIT, DISRUPTION
RP   PHENOTYPE, AND MUTAGENESIS OF SER-76; GLU-78; ARG-100; GLU-102; HIS-108;
RP   PHE-112; GLU-116; TYR-118; GLU-244 AND ARG-303.
RC   STRAIN=14028s / SGSC 2262, and LT2 / SGSC1412 / ATCC 700720;
RX   PubMed=20670890; DOI=10.1016/j.molcel.2010.06.021;
RA   Navarre W.W., Zou S.B., Roy H., Xie J.L., Savchenko A., Singer A.,
RA   Edvokimova E., Prost L.R., Kumar R., Ibba M., Fang F.C.;
RT   "PoxA, YjeK, and elongation factor P coordinately modulate virulence and
RT   drug resistance in Salmonella enterica.";
RL   Mol. Cell 39:209-221(2010).
CC   -!- FUNCTION: With EpmB is involved in the beta-lysylation step of the
CC       post-translational modification of translation elongation factor P (EF-
CC       P) on 'Lys-34'. Catalyzes the ATP-dependent activation of (R)-beta-
CC       lysine produced by EpmB, forming a lysyl-adenylate, from which the
CC       beta-lysyl moiety is then transferred to the epsilon-amino group of EF-
CC       P 'Lys-34' (Probable). Can also use L-alpha-lysine as a substrate, but
CC       probably with lower efficiency. Cannot aminoacylate tRNA(Lys) with
CC       lysine. {ECO:0000255|HAMAP-Rule:MF_00174, ECO:0000269|PubMed:20670890,
CC       ECO:0000305}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000255|HAMAP-Rule:MF_00174,
CC       ECO:0000269|PubMed:20670890}.
CC   -!- DISRUPTION PHENOTYPE: Mutants have a reduced pyruvate oxidase activity
CC       and a reduced growth rate, and are highly attenuated for virulence in
CC       mouse models of infection. Salmonella epmA and epmB mutants share
CC       extensive phenotypic pleiotropy, including an increased ability to
CC       respire under nutrient-limiting conditions, hypersusceptibility to a
CC       variety of diverse growth inhibitors, and altered expression of
CC       multiple proteins, including several encoded on the SPI-1 pathogenicity
CC       island. {ECO:0000269|PubMed:20670890, ECO:0000269|PubMed:9826331}.
CC   -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase family.
CC       EpmA subfamily. {ECO:0000255|HAMAP-Rule:MF_00174}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF001831; AAC82540.1; -; Genomic_DNA.
DR   EMBL; AE006468; AAL23167.1; -; Genomic_DNA.
DR   RefSeq; NP_463208.1; NC_003197.2.
DR   RefSeq; WP_000004794.1; NC_003197.2.
DR   PDB; 3G1Z; X-ray; 1.95 A; A/B=1-325.
DR   PDBsum; 3G1Z; -.
DR   SMR; Q9ZJ12; -.
DR   PaxDb; Q9ZJ12; -.
DR   EnsemblBacteria; AAL23167; AAL23167; STM4344.
DR   GeneID; 1255870; -.
DR   KEGG; stm:STM4344; -.
DR   PATRIC; fig|99287.12.peg.4571; -.
DR   HOGENOM; CLU_008255_1_1_6; -.
DR   OMA; EWYRPGF; -.
DR   PhylomeDB; Q9ZJ12; -.
DR   EvolutionaryTrace; Q9ZJ12; -.
DR   Proteomes; UP000001014; Chromosome.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0016880; F:acid-ammonia (or amide) ligase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004824; F:lysine-tRNA ligase activity; IBA:GO_Central.
DR   GO; GO:0000049; F:tRNA binding; IBA:GO_Central.
DR   GO; GO:0006430; P:lysyl-tRNA aminoacylation; IBA:GO_Central.
DR   GO; GO:0071915; P:protein-lysine lysylation; IEA:UniProtKB-UniRule.
DR   HAMAP; MF_00174; EF_P_modif_A; 1.
DR   InterPro; IPR004364; Aa-tRNA-synt_II.
DR   InterPro; IPR006195; aa-tRNA-synth_II.
DR   InterPro; IPR004525; EpmA.
DR   InterPro; IPR018149; Lys-tRNA-synth_II_C.
DR   Pfam; PF00152; tRNA-synt_2; 1.
DR   PRINTS; PR00982; TRNASYNTHLYS.
DR   TIGRFAMs; TIGR00462; genX; 1.
DR   PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Ligase; Nucleotide-binding; Reference proteome.
FT   CHAIN           1..325
FT                   /note="Elongation factor P--(R)-beta-lysine ligase"
FT                   /id="PRO_0000152728"
FT   NP_BIND         100..102
FT                   /note="ATP"
FT   NP_BIND         244..245
FT                   /note="ATP"
FT   REGION          76..78
FT                   /note="Substrate binding"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_00174"
FT   BINDING         109
FT                   /note="ATP; via amide nitrogen and carbonyl oxygen"
FT   BINDING         118
FT                   /note="Substrate"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_00174"
FT   BINDING         251
FT                   /note="Substrate"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_00174"
FT   BINDING         300
FT                   /note="ATP; via amide nitrogen"
FT                   /evidence="ECO:0000255|HAMAP-Rule:MF_00174"
FT   MUTAGEN         76
FT                   /note="S->A: Partial loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         78
FT                   /note="E->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         100
FT                   /note="R->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         102
FT                   /note="E->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         108
FT                   /note="H->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         112
FT                   /note="F->A: Partial loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         116
FT                   /note="E->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         118
FT                   /note="Y->A: No effect on activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         244
FT                   /note="E->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   MUTAGEN         303
FT                   /note="R->A: Loss of activity."
FT                   /evidence="ECO:0000269|PubMed:20670890"
FT   CONFLICT        31
FT                   /note="A -> G (in Ref. 1; AAC82540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        86
FT                   /note="A -> E (in Ref. 1; AAC82540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        158
FT                   /note="E -> G (in Ref. 1; AAC82540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        275
FT                   /note="P -> A (in Ref. 1; AAC82540)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        279
FT                   /note="I -> M (in Ref. 1; AAC82540)"
FT                   /evidence="ECO:0000305"
FT   HELIX           13..32
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          42..46
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          57..60
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          69..73
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           78..87
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          91..99
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          110..120
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           124..139
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          145..148
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           149..157
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   TURN            161..163
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           166..175
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           179..184
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           188..199
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           201..203
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          204..208
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          210..213
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           217..219
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          232..240
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          243..251
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           255..271
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           281..289
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          294..300
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           301..309
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   HELIX           314..316
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   STRAND          318..320
FT                   /evidence="ECO:0007744|PDB:3G1Z"
FT   TURN            322..324
FT                   /evidence="ECO:0007744|PDB:3G1Z"
SQ   SEQUENCE   325 AA;  36856 MW;  E90A3109EE388E4C CRC64;
     MSETATWQPS ASIPNLLKRA AIMAEIRRFF ADRGVLEVET PCMSQATVTD IHLFPFETRF
     VGPGHSQGIN LYLMTSPEYH MKRLLAAGCG PVFQLCRSFR NEEMGRHHNP EFTMLEWYRP
     HYDMYRLMNE VDDLLQQVLD CQPAESLSYQ QAFQRHLEID PLSADKTQLR EAAAKLDLSN
     IADTEEDRDT LLQLLFTMGV EPHIGKEKPT FIYHFPASQA SLAQISTEDH RVAERFEVYY
     KGIELANGFH ELTDAREQQQ RFEQDNRKRA ARGLPQQPID QNLLDALAAG LPDCSGVALG
     VDRLVMLALG AESLADVIAF TVDRA
//
